Physician profile
Flora Jane Brown
NPI 1861252413
$483.38
in general payments reported to CMS, 2019-2025
11 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $177 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $483.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $127.72 | 2024-2025 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $125.22 | 2024-2025 | |
| Abbvie INC. | $53.85 | 2024-2025 | |
| Novo Nordisk INC | $40.75 | 2025 | Ozempic, Rybelsus |
| Amgen INC. | $25.69 | 2024 | Krystexxa |
| Phathom Pharmaceuticals, INC. | $22.75 | 2025 | Voquezna |
| Lilly USA, LLC | $19.36 | 2024 | Jardiance |
| Abbott Laboratories | $17.96 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $17.57 | 2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $17.45 | 2025 | Aptima |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.06 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Flora Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.